10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q1 2023

Filing Information

Form Type	10-Q
Accession Number	`0001558370-23-009382`
Period End Date	20230331
Filing Date	20230511
Fiscal Year	2023
Fiscal Period	Q1
XBRL Instance	bpth-20230331x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 60 Income Statement 20 Cash Flow Statement 29 Stockholders Equity 12

Balance Sheet 60 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$10.38M	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$6.73M	USD	Point-in-time
Prepaid drug product	`PrepaidExpenseCurrent`	$3.59M	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product	`PrepaidExpenseCurrent`	$2.40M	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.64M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.66M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.62M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$10.79M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	7.16M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	7.96M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	7.96M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	7.16M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$1.12M	USD	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$1.12M	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$984.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$962.00K	USD	Point-in-time
Furniture, fixtures & equipment, net	`PropertyPlantAndEquipmentNet`	$158.00K	USD	Point-in-time
Furniture, fixtures & equipment, net	`PropertyPlantAndEquipmentNet`	$136.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$175.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$198.00K	USD	Point-in-time
Total Assets	`Assets`	$11.10M	USD	Point-in-time
Total Assets	`Assets`	$15.97M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$667.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$827.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$909.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$973.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$110.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$108.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.91M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.68M	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$113.00K	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$85.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.00M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.80M	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 7,960 and 7,160 shares issued and outstanding, respectively	`CommonStockValue`	$8.00K	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 7,960 and 7,160 shares issued and outstanding, respectively	`CommonStockValue`	$8.00K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$105.69M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$105.90M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-96.80M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-91.53M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$14.17M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$9.11M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$22.32M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$25.46M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$11.10M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$15.97M	USD	Point-in-time

Income Statement 20 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$3.99M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.10M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.26M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.30M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$5.29M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$3.36M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-3.36M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-5.29M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$19.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$19.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.27M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.36M	USD	1 Quarter
Net loss per share, basic (in dollars per share)	`EarningsPerShareBasic`	$-0.47	USD	1 Quarter
Net loss per share, basic (in dollars per share)	`EarningsPerShareBasic`	$-0.66	USD	1 Quarter
Weighted average number of common shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	7.16M	shares	1 Quarter
Weighted average number of common shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	7.96M	shares	1 Quarter
Net loss per share, diluted (in dollars per share)	`EarningsPerShareDiluted`	$-0.47	USD	1 Quarter
Net loss per share, diluted (in dollars per share)	`EarningsPerShareDiluted`	$-0.66	USD	1 Quarter
Weighted average number of common shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	7.96M	shares	1 Quarter
Weighted average number of common shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	7.16M	shares	1 Quarter

Cash Flow Statement 29 line items

Line Item	Tag	Value	Unit	Period
Net income loss	`NetIncomeLoss`	$-5.27M	USD	1 Quarter
Net income loss	`NetIncomeLoss`	$-3.36M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$206.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$217.00K	USD	1 Quarter
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$23.00K	USD	1 Quarter
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$23.00K	USD	1 Quarter
Depreciation	`Depreciation`	$22.00K	USD	1 Quarter
Depreciation	`Depreciation`	$22.00K	USD	1 Quarter
Prepaid drug product	`IncreaseDecreaseInPrepaidExpense`	$429.00K	USD	1 Quarter
Prepaid drug product	`IncreaseDecreaseInPrepaidExpense`	$-1.19M	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$20.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-433.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$224.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$591.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$24.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$26.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.53M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.65M	USD	1 Quarter
Net (decrease) increase in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-2.53M	USD	1 Quarter
Net (decrease) increase in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-3.65M	USD	1 Quarter
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.38M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.25M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.73M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.77M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.38M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.25M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.73M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.77M	USD	Point-in-time
Right of use asset recognized in exchange for lease obligation	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$85.00K	USD	1 Quarter

Stockholders Equity 12 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$14.17M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.11M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$22.32M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$25.46M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$217.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$206.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.27M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.36M	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$14.17M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.11M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$22.32M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$25.46M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.